PATENT CLAIM ANALYSIS

Application Number: 15880726
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "142100"]

Abstract:
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Claim (Index 21):
A method of treating a patient suffering from rheumatoid arthritis, said method comprising administering to said patient a pharmaceutical composition comprising an anti-GM-CSF antibody with pharmaceutically acceptable carriers, excipients or stabilizers, wherein the pharmaceutically acceptable carriers, excipients or stabilizers are a buffer which is histidine; a sugar which is sorbitol; and a non-ionic surfactant which is Tween-80, wherein said anti-GM-CSF antibody comprises an HCDR1 region of sequence GFTFSSYWMN (SEQ ID NO.: 2), an HCDR2 region of sequence GIENKYAGGATYYAASVKG (SEQ ID NO.: 3), an HCDR3 region of sequence GFGTDF (SEQ ID NO.: 4), an LCDR1 region of sequence SGDSIGKKYAY (SEQ ID NO.: 5), an LCDR2 region of sequence KKRPS (SEQ ID NO.: 6), and an LCDR3 region of sequence SAWGDKGM (SEQ ID NO.: 7).

Metadata:
- Claim Count in Document: 8.0
- Percentile: 86.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13877585', '15654854', '14904864', '12704396', '12157599']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.680627559488212
- 35 USC 102 Novelty (BERT): 0.5023408011406728
- Combined Prediction Score: 0.6627988836534581
- Mean Citation Score: 230.968688
- Max Citation Score: 254.1106
- Similarity Product: 181.2800348133921

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test